KPV 10MG

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation.

15 CLICKS = 500MCG

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols.

Goal : Support reduction of systemic inflammation and modulate immune responses without melanotropic effects.

Schedule : Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range : 200-500mcg daily with gradual weekly titration.

Dosing Protocol :
Suggested daily titration approach.

• Start : 200 mcg daily; increase by ~100 mcg weekly as tolerated.
• Target : 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects.
• Frequency : Once per day (subcutaneous).
• Cycle Length : 8–12 weeks; optional extension to 16 weeks under monitoring.
• Timing : Any consistent time; rotate injection sites systematically.